Canada Algernon receives approval to conduct DMT study in the Netherlands New clinical research will assess efficacy of IV formulation for the treatment of strokes Rowan DunneSeptember 12, 2022
Canada Optimi makes history with gargantuan psilocybin harvest Company believes it has completed the largest mushroom harvest Canada has ever seen Rowan DunneSeptember 9, 2022
Canada Mindset Pharma discovers 3 novel next-gen psychedelic compounds Discovery of new drugs follows company decision to extend research outside of tryptamine class, i.e. psilocybin and DMT Rowan DunneAugust 31, 2022
Canada Cybin administers psychedelic analogue to patients with major depression First novel psilocybin compound to commence clinical development marks 'tremendous milestone' for biotechnology company Rowan DunneAugust 30, 2022
Canada PharmAla Biotech applies for patent on 6 novel MDMA-like molecules Application follows successful pre-clinical animal studies at the University of Arkansas Rowan DunneAugust 29, 2022
Canada Clearmind’s psychoactive drug shows positive results for cocaine use disorder Novel proprietary psychedelic molecule continues to demonstrate potential for treating cocaine dependency Rowan DunneAugust 26, 2022
Canada Canntab Therapeutics enters the Nova Scotia cannabis marketplace Cannabinoid tablet supplier expands its Canadian distribution network Rowan DunneAugust 22, 2022
Canada PharmAla Biotech becomes first public company producing GMP MDMA Biotechnology organization will also supply LaNeo product to Australian research institute for clinical trial Rowan DunneAugust 22, 2022
Cannabis Cybin receives Schedule I DEA license for CYB003 trial New license is the final required step before administering doses to study participants Rowan DunneAugust 17, 2022
Canada Entourage Health signs agreement with Irwin Naturals for Canadian distribution New cannabinoid soft gel varieties from Irwin to be made available throughout Canada in the near future Rowan DunneAugust 4, 2022